Resources

Decisive Action needed to tackle chronic kidney disease (CKD)

Reasons to care

PA_Background

Chronic Kidney Disease (CKD) remains a largely unrecognised public health crisis, with fewer than 10% of those affected aware of their condition, potentially leading to severe outcomes such as dialysis, kidney transplant, or death[1][2]. Our quick read emphasises the urgent need for government, policymakers and commissioners to prioritise CKD as a critical health policy issue, aiming to improve patient outcomes and alleviate pressure on the NHS. Bayer calls for decisive action to address this invisible emergency and outlines ongoing efforts to combat the challenges of CKD.

Decisive Action needed to tackle CKD
Partnerships with Bayer - Targeting CKD
Addressing unmet need in chronic kidney disease. Kerendia®▼ (finerenone)
Partnerships with Bayer - Targeting CVD
Addressing unmet need in cardiovascular disease
Advancing Equitable & Sustainable Healthcare
Bayer developed resources to support reduction in variation, health inequalities and to optimise treatment in the NHS.
PP-MACS-GB-0165, August 2024

Abbreviations

CKD - Chronic Kidney Disease

CVD - Cardiovascular Disease

View Kerendia®▼ (finerenone)​ Prescribing Information

PP-KER-GB-0765 | November 2024


    • 1
      Chronic kidney disease - Driving change to address the urgent and silent epidemic in Europe (2023) Economist Impact. Available at: https://impact.economist.com/projects/chronic-kidney-disease/ (Accessed: June 2024).
    • 2
      GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709-733.